MedPath

Impact of reverse redistribution of technetium-99m-sestamibi in acute phase on improvement of left ventricular function, brain natriuretic peptide levels, exercise capacity, and prognosis in patients with acute coronary syndrome

Not Applicable
Conditions
Acute coronary syndrome
Registration Number
JPRN-UMIN000032436
Lead Sponsor
Gifu Prefectural General Medical Center
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up continuing
Sex
All
Target Recruitment
120
Inclusion Criteria

Not provided

Exclusion Criteria

Patients who did not undergo ultrasound echocardiography, laboratory test, and cardiopulmonary exercise test

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Major cardiac events including all cause death, life-threatening arrhythmia, and heart failure requiring hospitalization
Secondary Outcome Measures
NameTimeMethod
Improvement of LV function, BNP levels, exercise capacity in chronic phase (approximately 3 month after ACS)
© Copyright 2025. All Rights Reserved by MedPath